These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2887615)

  • 1. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 10. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome.
    Saeed ZA; Norton JA; Frank WO; Young MD; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1989 Jun; 96(6):1393-402. PubMed ID: 2565842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.
    Collen MJ; Howard JM; McArthur KE; Raufman JP; Cornelius MJ; Ciarleglio CA; Gardner JD; Jensen RT
    Ann Intern Med; 1984 Jan; 100(1):52-8. PubMed ID: 6318628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study.
    Richardson CT; Peters MN; Feldman M; McClelland RN; Walsh JH; Cooper KA; Willeford G; Dickerman RM; Fordtran JS
    Gastroenterology; 1985 Aug; 89(2):357-67. PubMed ID: 2861140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
    Jensen RT; Collen MJ; McArthur KE; Howard JM; Maton PN; Cherner JA; Gardner JD
    Am J Med; 1984 Nov; 77(5B):90-105. PubMed ID: 6150641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine and cimetidine in Zollinger-Ellison syndrome.
    Mignon M; Vallot T; Mayeur S; Bonfils S
    Br J Clin Pharmacol; 1980 Aug; 10(2):173-4. PubMed ID: 6107118
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
    Shiratori K; Watanabe S; Maruyama M; Adachi H; Itoh Y; Kurokawa K; Takeuchi T
    Nihon Shokakibyo Gakkai Zasshi; 1984 Jul; 81(7):1623-7. PubMed ID: 6149326
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of H2 antagonists in Zollinger-Ellison syndrome].
    Dammann HG; Walter TA; Müller P; Simon B
    Clin Ter; 1984 Dec; 111(5):393-400. PubMed ID: 6151434
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.